H
Hsiaoyin Mao
Researcher at Ohio State University
Publications - 24
Citations - 2960
Hsiaoyin Mao is an academic researcher from Ohio State University. The author has contributed to research in topics: Interleukin 12 & Interleukin 21. The author has an hindex of 19, co-authored 24 publications receiving 2633 citations. Previous affiliations of Hsiaoyin Mao include The Ohio State University Wexner Medical Center.
Papers
More filters
Journal ArticleDOI
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver
Shu-Hao Hsu,Bo Wang,Janaiah Kota,Jianhua Yu,Stefan Costinean,Huban Kutay,Lianbo Yu,Shoumei Bai,Shoumei Bai,Krista M. D. La Perle,Raghu R. Chivukula,Hsiaoyin Mao,Min Wei,K. Reed Clark,K. Reed Clark,Jerry R. Mendell,Jerry R. Mendell,Michael A. Caligiuri,Samson T. Jacob,Joshua T. Mendell,Kalpana Ghoshal +20 more
TL;DR: It is demonstrated that deletion of mouse Mir122 resulted in hepatosteatosis, hepatitis, and the development of tumors resembling HCC, demonstrating critical functions for miR-122 in the maintenance of liver homeostasis and have important therapeutic implications, including the potential utility of mi R-122 delivery for selected patients with HCC and the need for careful monitoring of patients receiving miR -122 inhibition therapy for HCV.
Journal ArticleDOI
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein
Paolo Neviani,Ramasamy Santhanam,Rossana Trotta,Mario Notari,Bradley W. Blaser,Shujun Liu,Hsiaoyin Mao,Ji Suk Chang,Annamaria Galietta,Ashwin Uttam,Denis C. Roy,Mauro Valtieri,Rebecca Bruner-Klisovic,Michael A. Caligiuri,Clara D. Bloomfield,Guido Marcucci,Danilo Perrotti +16 more
TL;DR: PP2A activation results in growth suppression, enhanced apoptosis, restored differentiation, impaired clonogenic potential, and decreased in vivo leukemogenesis of imatinib-sensitive and -resistant BCR/ABL+.
Journal ArticleDOI
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
Jianhong Chu,Youcai Deng,Don M. Benson,Shun He,Tiffany Hughes,Jianying Zhang,Yong Peng,Hsiaoyin Mao,Ling Yi,Kalpana Ghoshal,Xiaoming He,Steven M. Devine,Xiaoliu Zhang,Michael A. Caligiuri,Craig C. Hofmeister,Jianhua Yu +15 more
TL;DR: CS1 represents a viable target for CAR-expressing immune cells, and autologous or allogeneic transplantation of CS1-specific CAR NK cells may be a promising strategy to treat MM.
Journal ArticleDOI
Pro- and Antiinflammatory Cytokine Signaling: Reciprocal Antagonism Regulates Interferon-gamma Production by Human Natural Killer Cells
Jianhua Yu,Min Wei,Brian Becknell,Rossana Trotta,Shujun Liu,Zachary Boyd,Michael S. Jaung,Bradley W. Blaser,Jin Sun,Don M. Benson,Hsiaoyin Mao,Akihiko Yokohama,Darshna Bhatt,Lei Shen,Ramana V. Davuluri,Michael Weinstein,Guido Marcucci,Michael A. Caligiuri +17 more
TL;DR: It is suggested that pro- and antiinflammatory cytokine signaling reciprocally antagonize each other in an effort to prevail in the regulation of NK cell IFN-gamma production.
Journal ArticleDOI
TGF-β Utilizes SMAD3 to Inhibit CD16-Mediated IFN-γ Production and Antibody-Dependent Cellular Cytotoxicity in Human NK Cells
Rossana Trotta,Jessica Dal Col,Jianhua Yu,David Ciarlariello,Brittany Thomas,Xiaoli Zhang,Jeffrey Allard,Min Wei,Hsiaoyin Mao,John C. Byrd,Danilo Perrotti,Michael A. Caligiuri +11 more
TL;DR: Results indicate that TGF-β inhibits CD16-mediated human NK cell IFN-γ production and ADCC, and these effects are mediated via SMAD3.